Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
64 hedge funds and large institutions have $187M invested in Strongbridge Biopharma plc. in 2018 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 25 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
2% less funds holding
Funds holding: 65 → 64 (-1)
31% less capital invested
Capital invested by funds: $273M → $187M (-$85.6M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$10.1M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.93M |
| 3 |
Millennium Management
New York
|
+$3.84M |
| 4 |
Goldman Sachs
New York
|
+$2.62M |
| 5 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.32M |
| 2 |
AC
Armistice Capital
New York
|
-$8.88M |
| 3 |
BC
Broadfin Capital
New York
|
-$3.32M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.61M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$2.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
RhumbLine Advisers
Boston,
Massachusetts
| – | -$192K | -21,661 | Closed |
|
77
Citadel Advisors
Miami,
Florida
| – | -$166K | -18,813 | Closed |
|
|
AIG
78
American International Group
New York
| – | -$159K | -17,911 | Closed |
|
79
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$142K | -16,000 | Closed |
|
80
VOYA Investment Management
Atlanta,
Georgia
| – | -$115K | -13,012 | Closed |
|
|
CS
81
Credit Suisse
Zurich,
Switzerland
| – | -$112K | -12,681 | Closed |
|
82
Stifel Financial
St. Louis,
Missouri
| – | -$96K | -10,884 | Closed |
|
83
JP Morgan Chase
New York
| – | -$66K | -7,503 | Closed |
|
|
SO
84
STRS Ohio
Columbus,
Ohio
| – | -$56K | -6,400 | Closed |
|
85
BNP Paribas Financial Markets
Paris,
France
| – | -$48.4K | -5,472 | Closed |
|
86
Legal & General Group
London,
United Kingdom
| – | -$40K | -4,587 | Closed |
|
|
AIP
87
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$17K | -1,924 | Closed |
|
|
MAM
88
Meeder Asset Management
Dublin,
Ohio
| – | -$1K | -101 | Closed |
|
SBBP Hedge Fund Activity: Q2 2018 in Review
64 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q2 2018, worth a combined $187M — down 31% from $273M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SBBP and 24 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 19 added.
The largest buyer was Lyon Street Capital, adding an estimated $10.1M. The largest seller was BlackRock, cutting an estimated $9.32M.
- 64 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q2 2018, down from 65 in Q1 2018.
- Funds reported $187M of Strongbridge Biopharma plc. stock for Q2 2018, down 31% quarter-over-quarter.
- 24 funds opened new Strongbridge Biopharma plc. positions in Q2 2018 and 25 closed out, a net change of -1 holder.
- The largest Strongbridge Biopharma plc. buyer in Q2 2018 was Lyon Street Capital, an estimated $10.1M added.
- The largest Strongbridge Biopharma plc. seller in Q2 2018 was BlackRock, an estimated $9.32M sold.
Based on aggregated 13F filings for Q2 2018.